Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial
Journal of Allergy and Clinical Immunology · 2023-11 · 152 (5) · 1121-1130.e10
DOI: 10.1016/j.jaci.2023.05.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-11. Verfasst von Salman Siddiqui und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College, London, United Kingdom. Hauptthemen laut MEDLINE: Asthma, Pulmonary Eosinophilia, Anti-Asthmatic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: There is a need for new and effective oral asthma therapies. Dexpramipexole, an oral eosinophil-lowering drug, has not previously been studied in asthma. OBJECTIVE: We sought to evaluate the safety and efficacy of dexpramipexole in lowering blood and airway eosinophilia in subjects with eosinophilic asthma. METHODS: We performed a randomized, double-blind, placebo-controlled proof-of-concept trial in adults with inadequately controlled moderate to severe asthma and blood absolute eosinophil count (AEC) greater than or equal to 300/μL. Subjects were randomly assigned (1:1:1:1) to dexpramipexole 37.5, 75, or 150 mg BID (twice-daily) or placebo. The primary end point was the relative change in AEC from baseline to week 12. Prebronchodilator FEV1 week-12 change from baseline was a key secondary end point. Nasal eosinophil peroxidase was an exploratory end point. RESULTS: A total of 103 subjects were randomly assigned to dexpramipexole 37.5 mg BID (N = 22), 75 mg BID (N = 26), 150 mg BID (N = 28), or placebo (N = 27). Dexpramipexole significantly reduced placebo-corrected AEC week-12 ratio to baseline, in both the 150-mg BID (ratio, 0.23; 95% CI, 0.12-0.43; P < .0001) and the 75-mg BID (ratio, 0.34; 95% CI, 0.18-0.65; P = .0014) dose groups, corresponding to 77% and 66% reductions, respectively. Dexpramipexole reduced the exploratory end point of nasal eosinophil peroxidase week-12 ratio to baseline in the 150-mg BID (median, 0.11; P = .020) and the 75-mg BID (median, 0.17; P = .021) groups. Placebo-corrected FEV1 increases were observed starting at week 4 (nonsignificant). Dexpramipexole displayed a favorable safety profile. CONCLUSIONS: Dexpramipexole demonstrated effective eosinophil lowering and was well tolerated. Additional larger clinical trials are needed to understand the clinical efficacy of dexpramipexole in asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Imperial College, London, United Kingdom.
- University of Pittsburgh School of Public Health, Environmental & Occupational Health, Pittsburgh, Pa.
- Knopp Biosciences, LLC, Pittsburgh, Pa.
- Division of Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Division of Allergy, Asthma and Clinical Immunology, Scottsdale, Ariz; Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz.
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Zitieren
APA
Siddiqui, S., Wenzel, S. E., Bozik, M. E., Archibald, D. G., Dworetzky, S. I., Mather, J. L., Killingsworth, R., Ghearing, N., Schwartz, J. T., Ochkur, S. I., Jacobsen, E. A., Busse, W. W., Panettieri, R. A., & Prussin, C. (2023). Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial. Journal of Allergy and Clinical Immunology, 152(5), 1121-1130.e10. https://doi.org/10.1016/j.jaci.2023.05.014
Vancouver
Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, et al. Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial. Journal of Allergy and Clinical Immunology. 2023;152(5):1121-1130.e10. doi:10.1016/j.jaci.2023.05.014
BibTeX
@article{Siddiqui2023,
author = {Siddiqui, Salman and Wenzel, Sally E and Bozik, Michael E and Archibald, Donald G and Dworetzky, Steven I and Mather, James L and Killingsworth, Randall and Ghearing, Natasha and Schwartz, Justin T and Ochkur, Sergei I and Jacobsen, Elizabeth A and Busse, William W and Panettieri, Reynold A and Prussin, Calman},
title = {Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {5},
pages = {1121--1130.e10},
doi = {10.1016/j.jaci.2023.05.014}
}
EUVIMED